Biopharma Business

Tag "Biogen"

Biogen takes up option to co-develop Eisai AD drug

    Biogen takes up option to co-develop Eisai AD drug

Biogen and Eisai have expanded their existing collaboration agreement to develop and commercialise investigational therapies for Alzheimer’s Disease. Eisai has taken up its option to co-develop and co-promote aducanumab, Biogen’s

Read Full Article

Biogen Wins Full EC Approval for MS Drug Fampyra

    Biogen Wins Full EC Approval for MS Drug Fampyra

The EC granted full marketing approval for Biogen’s Fampyra® (prolonged-release fampridine) as a treatment to improve walking in people with multiple sclerosis (MS). Clearance in Europe was based on the

Read Full Article

Biogen to remain leader in neurodegenerative drugs

Roche’a anticipated approval of ocrelizumab will drive the company’s share of the market from <1% in 2016 to 15% by 2022, according to GBI Research The company’s report states that

Read Full Article

Irish State risks missing out on huge savings from generic drugs

The Irish Government risks losing out on hundreds of millions of euro in savings on its drug bill because of the failure to buy generic alternatives to expensive branded drugs.

Read Full Article

Upcoming Events

  • No upcoming events
AEC v1.0.4

The Magazine

New Subscriber





Subscribe Here



Advertisements